Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
07 Agosto 2024 - 7:00AM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, today announced that it will
participate in a panel focused on hereditary angioedema (HAE) at
the 2024 Wedbush PacGrow Healthcare Conference on August 14 in New
York, NY.
Jill C. Milne, Ph.D., Chief Executive Officer, will participate
in a panel titled, “HAE Ya! The Changing Face of the HAE
Therapeutic Landscape” on Wednesday, August 14 at 2:30pm ET.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240807566138/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Astria Therapeutics (NASDAQ:ATXS)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024
